Chippenham-based specialist drug firm Vectura has received a €1.5m (£1.18m) ‘milestone’ payment after securing approval in Portugal for its innovative respiratory inhaler AirFluSal Forspiro. Vectura’s partner Sandoz, the Swiss-owned global leader in generic medicines, has been granted marketing authorisation by the Portuguese Health Authority for the new inhaler aimed at patients with asthma and/or...